Core Viewpoint - IGM Biosciences, Inc. has entered into a definitive merger agreement with Concentra Biosciences, LLC, where Concentra will acquire IGM Biosciences for $1.247 in cash per share, along with contingent value rights [1][2] Group 1: Merger Agreement Details - The acquisition price includes $1.247 in cash per share of IGM Biosciences common stock and one non-tradeable contingent value right (CVR) [1] - The CVR entitles holders to receive 100% of IGM Biosciences' closing net cash exceeding $82.0 million and 80% of net proceeds from the disposition of certain product candidates and intellectual property within one year post-closing [1] - The IGM Biosciences Board of Directors has unanimously approved the merger agreement, deeming it in the best interests of all stockholders [2] Group 2: Tender Offer and Closing Conditions - Concentra will initiate a tender offer by July 16, 2025, to acquire all outstanding shares of IGM Biosciences common stock [3] - The closing of the tender offer is contingent upon the tender of voting common stock representing at least a majority of outstanding shares and the availability of at least $82.0 million in cash [3] - The merger transaction is anticipated to close in August 2025, subject to customary closing conditions [3] Group 3: Legal Advisors - Wilson Sonsini Goodrich & Rosati, P.C. is serving as legal counsel for IGM Biosciences, while Gibson, Dunn & Crutcher LLP is acting as legal counsel for Concentra [4]

SAN RAFAEL, Calif., July 1, 2025 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) said today that it completed the previously announced agreement to acquire Inozyme Pharma, Inc. (Nasdaq: INZY) for $4.00 per share in an all-cash transaction worth approximately $270 million. The acquisition will strengthen BioMarin's enzyme therapies portfolio, adding a late-stage enzyme replacement therapy, INZ-701. The medicine is currently being developed for the treatment of ectonucleotide pyrophosphatase/phosp ...

上半年，拿地排名TOP100房企在土拍市场共耗资5065.5亿元，同比增长33.3%，自2022年以来出现罕见的正增长。 但金额的同比增长，是靠各城上架了大量城市核心区优质地块换来的。如果以住宅用地成交面积计算，中指研究院统计的300城住宅用地成交面积仍在继 续缩量。 同时，房企也在进一步向重点一二线城市聚焦，尤其是北上广深、杭州、成都等几个热门城市。 未来，楼市的基本盘在头部20-30个城市。上半年，TOP20城市出让金在全国的占比已经超过65%，其它所有城市之和才占到1/3。 对于房企，楼市"战场"空间变小了，在这些城市的土地市场上正面交锋、硬碰硬不可避免。 一方面，头部房企之间的竞争加剧，是频频推高优质地块的溢价率高企的主要原因，后果是：企业做项目的成本越来越高； 另一方面，"资金+操盘"实力稍弱，会很快被挤出第一梯队。能让房企跑赢的已经不是某一年的爆发力，而是持续的资金续航和产品升级能力。 值得注意的是，TOP100房企权益拿地金额的中位数只有约20亿元，TOP1的权益拿地金额，已经达到了第30位的14.8倍。现在及未来，还有能力在多个城 市群全面深耕的房企也就20家左右，在全国热门城市多点开花已经和 ...

Core Insights - AZZ Inc. has announced the acquisition of Canton Galvanizing, LLC, enhancing its hot-dip galvanizing capabilities in the Midwest [1][2] - The acquisition is expected to be accretive to earnings within the first year and will increase AZZ's galvanizing network to 42 sites across North America [1][2] Company Overview - AZZ Inc. is a leading independent provider of hot-dip galvanizing and coil coating solutions, serving a wide range of end-markets [4] - The company focuses on providing sustainable metal coating solutions that enhance the longevity and appearance of essential infrastructure and products [4] Canton Galvanizing Overview - Canton Galvanizing, founded in 2019, specializes in hot-dip galvanizing for small to mid-size parts and is known for its quick turnaround times and excellent customer service [3]

Core Viewpoint - Teleflex Incorporated has successfully completed the acquisition of substantially all of the Vascular Intervention business from BIOTRONIK SE & Co. KG, enhancing its portfolio and global presence in the cath lab and peripheral intervention market [1][3][5]. Acquisition Details - The acquisition was finalized for a cash payment of €760 million, subject to certain adjustments [2]. - The Vascular Intervention business includes a comprehensive portfolio for coronary and peripheral interventions, featuring key products such as the Pantera™ Lux™ Drug-Coated Balloon Catheter and the Orsiro™ Mission Drug Eluting Stent [3][4]. Financial Outlook - The acquired products are expected to generate revenues of €177 million ($204 million) in the second half of 2025, with an anticipated €91 million ($105 million) for the fourth quarter of 2025 [5]. - From 2026 onwards, annual constant currency revenue growth of 6% or better is expected from the acquired products [5][6]. Strategic Implications - The acquisition will allow Teleflex to invest in the clinical trial program for Freesolve™, a sirolimus-eluting Resorbable Metallic Scaffold technology, with plans for a U.S. pivotal study [4]. - The integration of the Vascular Intervention business is anticipated to enhance Teleflex's innovation pipeline and position the company to leverage emerging technologies in the market [3][4].

Core Viewpoint - Cadence Bank has successfully completed the acquisition of Industry Bancshares, enhancing its presence in Texas and expanding its service offerings across more than 380 branches and over 400 ATM locations [1][2][5]. Group 1: Acquisition Details - The acquisition of Industry Bancshares, which includes several banks, was finalized on July 1, 2025, after receiving necessary regulatory and shareholder approvals [1][2]. - Industry Bancshares reported total assets of $4.4 billion, total loans of $1.1 billion, and total deposits of $4.5 billion as of March 31, 2025 [5]. Group 2: Strategic Benefits - The merger is expected to create growth opportunities for customers and communities, leveraging Cadence Bank's strong balance sheet and diverse product offerings [2][4]. - The combination of both companies aims to provide stability and consistency in banking operations and enhance liquidity for lending in the acquired markets [2][4]. Group 3: Customer Experience - Customers of Industry Bancshares will not see immediate changes in their banking experience and can continue using existing services until further integration updates are provided in the fall of 2025 [3][4]. - Customer deposit accounts will remain insured by the FDIC, with specific insurance provisions for time deposits from the acquired banks [4]. Group 4: Company Overview - Cadence Bank is a regional financial services company with over $52 billion in assets, offering a wide range of banking, investment, trust, and mortgage products [6]. - The company has been recognized as one of the nation's best employers and as one of America's Best Banks in 2025 [6].

Australia’s Swyftx to Acquire Caleb & Brown in Record $66M ANZ Crypto Deal► https://t.co/oRw2JCBJwm https://t.co/oRw2JCBJwm ...

Aviva’s plan to buy Direct Line Insurance for roughly £3.7 billion to create the UK’s largest motor insurer has been given the nod from the country’s competition regulator https://t.co/6XmhWPYa4e ...

I’ve spoken about this a *lot*Last week we saw Aiz get acqui-hired at gigaverse.Hearing rumors of a couple other high profile acquisitions in the works as well.Demonstrated, *REAL* following and influence is one of the most scarce resources in the age of AI, and it can’t be bought.Stay tunedcoinbilly (@coinbilly_):Twitter really is the best marketing and networking tool of our generation.If you need anything in your professional life, a decent Twitter following can most likely find it or do it for you. ...

Do you have a news tip for Investopedia reporters? Please email us at "Following careful consideration of The Home Depot's proposal, along with other potential opportunities for the Company, our Board determined that this transaction is in the best interests of GMS and all of our shareholders," GMS Chair John Gavin said. GMS shares soared 12% in intraday trading to $108.79 and have risen almost 30% this year. Home Depot shares slipped 0.8%, while QXO stock is up 3%. "The combination of GMS and SRS will prov ...